LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 120

Search options

  1. Article: The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic.

    Petrone, Linda / Sette, Alessandro / de Vries, Rory D / Goletti, Delia

    Pathogens (Basel, Switzerland)

    2023  Volume 12, Issue 7

    Abstract: Neutralizing antibodies are considered a correlate of protection against SARS-CoV-2 infection and severe COVID-19, although they are not the only contributing factor to immunity: T-cell responses are considered important in protecting against severe ... ...

    Abstract Neutralizing antibodies are considered a correlate of protection against SARS-CoV-2 infection and severe COVID-19, although they are not the only contributing factor to immunity: T-cell responses are considered important in protecting against severe COVID-19 and contributing to the success of vaccination effort. T-cell responses after vaccination largely mirror those of natural infection in magnitude and functional capacity, but not in breadth, as T-cells induced by vaccination exclusively target the surface spike glycoprotein. T-cell responses offer a long-lived line of defense and, unlike humoral responses, largely retain reactivity against the SARS-CoV-2 variants. Given the increasingly recognized role of T-cell responses in protection against severe COVID-19, the circulation of SARS-CoV-2 variants, and the potential implementation of novel vaccines, it becomes imperative to continuously monitor T-cell responses. In addition to "classical" T-cell assays requiring the isolation of peripheral blood mononuclear cells, simple whole-blood-based interferon-γ release assays have a potential role in routine T-cell response monitoring. These assays could be particularly useful for immunocompromised people and other clinically vulnerable populations, where interactions between cellular and humoral immunity are complex. As we continue to live alongside COVID-19, the importance of considering immunity as a whole, incorporating both humoral and cellular responses, is crucial.
    Language English
    Publishing date 2023-06-22
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2695572-6
    ISSN 2076-0817
    ISSN 2076-0817
    DOI 10.3390/pathogens12070862
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Multiple Hospital In-Situ Mass Casualty Incident Training Simulation for Emergency Medicine Residents: A Sarin Bomb Scenario.

    Musisca, Nicholas J / Rybasack-Smith, Heather / Musits, Andrew / Petrone, Gianna / Wightman, Rachel S / Smith, Jessica L / Brown, Linda L / Foggle, John L

    Rhode Island medical journal (2013)

    2023  Volume 106, Issue 9, Page(s) 36–40

    Abstract: Introduction: We simulated an on-site, multi-hospital mass casualty incident (MCI) to educate emergency medicine providers in the principles of trauma resuscitation and collaboration with administration and staff during an MCI.: Methods: We ... ...

    Abstract Introduction: We simulated an on-site, multi-hospital mass casualty incident (MCI) to educate emergency medicine providers in the principles of trauma resuscitation and collaboration with administration and staff during an MCI.
    Methods: We implemented high-fidelity manikins, inflatable manikins, and actors to simulate a sarin gas bombing. Learners triaged patients at a decontamination tent using the simple triage and rapid treatment (START) tool, or they participated in a simulation in a resuscitation bay.
    Results: Forty participants anonymously rated the learning impact of the exercise, the clinical relevance to emergency medicine, and the effectiveness of the faculty facilitation and debriefing on a 1-5 Likert scale. The average responses to all questions were 4.45 or greater, and 98% of respondents recommended adding the scenario to the standard curriculum.
    Discussion: We successfully executed a novel, multi- hospital, MCI drill that was rated to be a better alternative to sequential simulation in a simulation center.
    MeSH term(s) Humans ; Sarin ; Mass Casualty Incidents ; Curriculum ; Emergency Medicine ; Hospitals
    Chemical Substances Sarin (B4XG72QGFM)
    Language English
    Publishing date 2023-10-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 419430-5
    ISSN 2327-2228 ; 0363-7913
    ISSN (online) 2327-2228
    ISSN 0363-7913
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: The definition of tuberculosis infection based on the spectrum of tuberculosis disease.

    Migliori, Giovanni Battista / Ong, Catherine W M / Petrone, Linda / D'Ambrosio, Lia / Centis, Rosella / Goletti, Delia

    Breathe (Sheffield, England)

    2022  Volume 17, Issue 3, Page(s) 210079

    Abstract: Latent tuberculosis infection was the term traditionally used to indicate tuberculosis (TB) infection. This term was used to define "a state of persistent immune response to stimulation by : Educational aims: To describe the evolution of the ... ...

    Abstract Latent tuberculosis infection was the term traditionally used to indicate tuberculosis (TB) infection. This term was used to define "a state of persistent immune response to stimulation by
    Educational aims: To describe the evolution of the definition of "tuberculosis infection" and didactically describe the continuum of stages existing between TB infection and disease.To discuss the recommended approaches to prevent, diagnose and treat TB infection.
    Language English
    Publishing date 2022-01-10
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2562899-9
    ISSN 2073-4735 ; 1810-6838
    ISSN (online) 2073-4735
    ISSN 1810-6838
    DOI 10.1183/20734735.0079-2021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases.

    Cantini, Fabrizio / Blandizzi, Corrado / Niccoli, Laura / Petrone, Linda / Goletti, Delia

    Expert opinion on drug safety

    2020  Volume 19, Issue 7, Page(s) 861–872

    Abstract: Introduction: Janus kinases inhibitors (anti-JAKs), including tofacitinib, baricitinib, upadacitinib, and filgotinib, represent a new class of synthetic targeted drugs for the treatment of rheumatoid arthritis (RA). In this review, the risk of active ... ...

    Abstract Introduction: Janus kinases inhibitors (anti-JAKs), including tofacitinib, baricitinib, upadacitinib, and filgotinib, represent a new class of synthetic targeted drugs for the treatment of rheumatoid arthritis (RA). In this review, the risk of active tuberculosis (TB) occurrence in patients receiving anti-JAKs was assessed. The literature on this topic, updated to 29 February 2020 was reviewed. Overall, 40 reports (22 tofacitinib, 10 baricitinib, 5 upadacitinib, 3 filgotinib) were examined. A low frequency, not exceeding 0.25%, of active TB cases in patients were exposed to anti-JAKs. Only 1 of 89 recorded cases in tofactinib and baricitinib exposure occurred in countries at intermediate or high TB risk, and most of the cases probably were due to first mycobacterium tuberculosis (Mtb) exposure. Although no cases were observed in patients receiving upadacitinib and filgotinib, long-term trials and data from real-life are required to more precisely address the TB risk associated with the two drugs.
    Areas covered: Discussion on the TB risk associated with anti-JAKs, and on the need for accurate evaluation of host-related risk factors in high risk countries.
    Expert opinion: Available data on anti-JAKs suggest a negligible risk of active TB occurrence in low endemic areas.
    MeSH term(s) Antirheumatic Agents/administration & dosage ; Antirheumatic Agents/adverse effects ; Arthritis, Rheumatoid/drug therapy ; Humans ; Janus Kinase Inhibitors/administration & dosage ; Janus Kinase Inhibitors/adverse effects ; Risk ; Tuberculosis/epidemiology ; Tuberculosis/etiology
    Chemical Substances Antirheumatic Agents ; Janus Kinase Inhibitors
    Language English
    Publishing date 2020-06-17
    Publishing country England
    Document type Journal Article ; Systematic Review
    ZDB-ID 2088728-0
    ISSN 1744-764X ; 1474-0338
    ISSN (online) 1744-764X
    ISSN 1474-0338
    DOI 10.1080/14740338.2020.1774550
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Immune-Guided Therapy of COVID-19.

    Ferraccioli, Gianfranco / Gremese, Elisa / Goletti, Delia / Petrone, Linda / Cantini, Fabrizio / Ugel, Stefano / Canè, Stefania / Bronte, Vincenzo

    Cancer immunology research

    2022  Volume 10, Issue 4, Page(s) 384–402

    Abstract: Vaccination has been a game changer in our efforts to address the coronavirus disease 2019 (COVID-19) pandemic. However, the disease might still represent a clinical crisis for several more years, in part because of the inevitable emergence of variants ... ...

    Abstract Vaccination has been a game changer in our efforts to address the coronavirus disease 2019 (COVID-19) pandemic. However, the disease might still represent a clinical crisis for several more years, in part because of the inevitable emergence of variants capable of evading the preexisting immunity. Drugs affecting viral spread will help curtail transmission, but therapeutics are needed to treat the more severe cases requiring hospitalization. A deep analysis of the evolving immune landscape of COVID-19 suggests that understanding the molecular bases of the distinct clinical stages is paramount if we are to limit the burden of inflammation, which can lead to death in frail individuals, according to age, sex, and comorbidities. Different phases can be defined using immune biomarkers and need specific therapeutic approaches, tailored to the underlying immune contexture.
    MeSH term(s) COVID-19 ; Hospitalization ; Humans ; Pandemics ; SARS-CoV-2 ; Vaccination
    Language English
    Publishing date 2022-01-22
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2732489-8
    ISSN 2326-6074 ; 2326-6066
    ISSN (online) 2326-6074
    ISSN 2326-6066
    DOI 10.1158/2326-6066.CIR-21-0675
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Antigen discovery by bioinformatics analysis and peptide microarray for the diagnosis of cystic echinococcosis.

    Batisti Biffignandi, Gherard / Vola, Ambra / Sassera, Davide / Najafi-Fard, Saeid / Gomez Morales, Maria Angeles / Brunetti, Enrico / Teggi, Antonella / Goletti, Delia / Petrone, Linda / Tamarozzi, Francesca

    PLoS neglected tropical diseases

    2023  Volume 17, Issue 4, Page(s) e0011210

    Abstract: Background: Cystic echinococcosis (CE), caused by Echinococcus granulosus sensu lato, is a neglected zoonosis. Its diagnosis relies on imaging, supported by serology, while only imaging is useful for staging and follow-up. Since diagnostic tools and ... ...

    Abstract Background: Cystic echinococcosis (CE), caused by Echinococcus granulosus sensu lato, is a neglected zoonosis. Its diagnosis relies on imaging, supported by serology, while only imaging is useful for staging and follow-up. Since diagnostic tools and expertise are not widely available, new accurate and easily implementable assays for the diagnosis and follow-up of CE are highly needed.
    Methodology/principal findings: We aimed to identify new E. granulosus antigens through a bioinformatics selection applied to the parasite genome, followed by peptide microarray screening and validation in ELISA, using independent panels of sera from patients with hepatic CE and clinically relevant controls. From 950 proteins selected in silico, 2,379 peptides were evaluated by microarray for IgG reactivity and eight candidates selected for validation. Reactivity to one peptide was significantly higher in the CE group (p = 0.044), but had suboptimal diagnostic accuracy.
    Conclusions/significance: Here we performed bioinformatics analysis and peptide microarray for antigen discovery, useful for the diagnosis of CE. Eight candidates were selected and validated. Reactivity to one peptide associated to CE but had suboptimal diagnostic accuracy. Importantly, the database developed in this study may be used to identify other antigenic candidates for CE diagnosis and follow-up.
    MeSH term(s) Animals ; Humans ; Antigens, Helminth ; Echinococcosis/diagnosis ; Echinococcus granulosus ; Peptides ; Enzyme-Linked Immunosorbent Assay/methods ; Computational Biology
    Chemical Substances Antigens, Helminth ; Peptides
    Language English
    Publishing date 2023-04-12
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2429704-5
    ISSN 1935-2735 ; 1935-2735
    ISSN (online) 1935-2735
    ISSN 1935-2735
    DOI 10.1371/journal.pntd.0011210
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Alternative biomarkers of tuberculosis infection in patients with immune-mediated inflammatory diseases.

    Petruccioli, Elisa / Petrone, Linda / Najafi-Fard, Saeid / Navarra, Assunta / Vanini, Valentina / Cuzzi, Gilda / Cantini, Fabrizio / Gualano, Gina / Palmieri, Fabrizio / Goletti, Delia

    Frontiers in medicine

    2023  Volume 10, Page(s) 1271632

    Abstract: Introduction: IFN-γ release assays (IGRAs) are one of the referral tests for diagnosing tuberculosis infection (TBI). To improve IGRAs accuracy, several markers have been investigated. Patients with immune-mediated inflammatory diseases (IMID), taking ... ...

    Abstract Introduction: IFN-γ release assays (IGRAs) are one of the referral tests for diagnosing tuberculosis infection (TBI). To improve IGRAs accuracy, several markers have been investigated. Patients with immune-mediated inflammatory diseases (IMID), taking biological drugs, have a higher risk to progress to TB-disease compared to the general population. In several guidelines, annual TBI screening is recommended for patients undergoing biological therapy. Aim of this study was to investigate, within the QuantiFERON-TB-Plus (QFT-Plus) platform, if beside IFN-γ, alternative biomarkers help to diagnose TBI-IMID patients.
    Methods: We enrolled 146 subjects: 46 with TB disease, 20 HD, 35 with TBI and 45 with TBI and IMID. Thirteen IMID subjects with a QFT-Plus negative result were diagnosed as TBI based on radiological evidence of TBI. We evaluated the IP-10 level in response to TB1 and TB2 peptides of QFT-Plus assay and we compared these results with the standardized assay based on IFN-γ. Multiplex immune assay was performed on plasma from TB1 and TB2 tubes and results were analyzed by a gradient boosting machine (GBM) as learning technique.
    Results: TBI-IMID showed a significant decreased IP-10 level in response to TB1 and TB2 stimulation compared to TBI-NO IMID (
    Discussion: To develop alternative strategies for TBI immune-diagnosis, future studies are needed to evaluate the memory response of TBI defined by radiological tools. These results may help in tuberculosis management of patients taking lifelong immune-suppressive drugs.
    Language English
    Publishing date 2023-11-23
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2023.1271632
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice.

    Cantini, Fabrizio / Niccoli, Laura / Capone, Alessandro / Petrone, Linda / Goletti, Delia

    Expert opinion on drug safety

    2019  Volume 18, Issue 5, Page(s) 415–425

    Abstract: Introduction: Two classes of biologics, anti-tumor necrosis factor (TNF) and non-anti-TNF targeted, are currently available for the treatment of rheumatic diseases.: Areas covered: Discussion on the need for LTBI diagnosis in rheumatic patients ... ...

    Abstract Introduction: Two classes of biologics, anti-tumor necrosis factor (TNF) and non-anti-TNF targeted, are currently available for the treatment of rheumatic diseases.
    Areas covered: Discussion on the need for LTBI diagnosis in rheumatic patients treated csDMARDs and non-anti-TNFs through a review of the literature. The literature, updated to 15 April 2019, on tuberculosis (TB) reactivation risk in patients exposed to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and non-anti-TNF biologics was reviewed.
    Expert opinion: An increased risk of TB reactivation in patients receiving csDMARDs (except sulphasalazine) resulted, while a review of clinical trials, and Periodic Safety Update Reports from pharmaceutical Companies evidenced a very low or absent risk for non-anti-TNF biologics. Hence, a contradiction emerges considering that latent TB infection (LTBI) screening is recommended for non-anti-TNF candidates but not for csDMARDs. Concerning the low TB incidence countries, several actions could be undertaken, including to screen all patients independently on the treatment, to omit the procedure in non-anti-TNF candidates, or to perform the LTBI investigations only in high-risk patients. According to WHO guidelines, LTBI screening in low TB risk countries seems unnecessary, except in high TB risk subjects.
    MeSH term(s) Antirheumatic Agents/adverse effects ; Antirheumatic Agents/pharmacology ; Antirheumatic Agents/therapeutic use ; Biological Products/adverse effects ; Biological Products/therapeutic use ; Humans ; Latent Tuberculosis/diagnosis ; Latent Tuberculosis/etiology ; Mass Screening/methods ; Practice Guidelines as Topic ; Rheumatic Diseases/drug therapy ; Risk Factors ; Tuberculosis/diagnosis ; Tuberculosis/etiology
    Chemical Substances Antirheumatic Agents ; Biological Products
    Language English
    Publishing date 2019-05-08
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2088728-0
    ISSN 1744-764X ; 1474-0338
    ISSN (online) 1744-764X
    ISSN 1474-0338
    DOI 10.1080/14740338.2019.1612872
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Interdepartmental Collaboration for Simulation-based Education: Obstetric Emergencies for Emergency Medicine.

    Musits, Andrew / Wing, Robyn / Simoes, Meera / Style, Michele / Petrone, Gianna / Musisca, Nick / Brown, Linda

    Rhode Island medical journal (2013)

    2020  Volume 103, Issue 4, Page(s) 42–45

    Abstract: Background: Simulation in medical education is a well-accepted educational modality that allows for practice of high risk, low frequency events. The Obstetric Emergencies for Emergency Medicine course was developed to prepare trainees for challenging ... ...

    Abstract Background: Simulation in medical education is a well-accepted educational modality that allows for practice of high risk, low frequency events. The Obstetric Emergencies for Emergency Medicine course was developed to prepare trainees for challenging scenarios.
    Methods: Six clinical scenarios were chosen: spontaneous vaginal delivery, neonatal resuscitation, pre- eclampsia, neonatal resuscitation with cardiopulmonary resuscitation (CPR), shoulder dystocia and postpartum hemorrhage. Development and facilitation was an interdepartmental effort with contributions from Emergency Medicine, Obstetrics and Gynecology, and Pediatric Emergency Medicine. Each case was allotted 35 minutes, including debriefing. Participants completed an evaluation survey for each scenario.
    Results: All participants responded yes to the question "Would you recommend this simulation become part of the standard curriculum." The means of ratings for "scenario overall" and "relevance to training/duties" ranged from 4.95-5 out of 5 across all simulation groups.
    Conclusion: An interdepartmental and collaborative approach can optimize the success of a simulation educational program.
    MeSH term(s) Clinical Competence ; Curriculum ; Delivery, Obstetric/education ; Dystocia/therapy ; Eclampsia/therapy ; Education, Medical/methods ; Emergency Treatment ; Female ; Health Personnel/education ; Humans ; Infant, Newborn ; Manikins ; Obstetric Labor Complications/therapy ; Obstetrics/education ; Patient Care Team ; Postpartum Hemorrhage/therapy ; Pregnancy ; Resuscitation/methods ; Simulation Training
    Language English
    Publishing date 2020-05-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 419430-5
    ISSN 2327-2228 ; 0363-7913
    ISSN (online) 2327-2228
    ISSN 0363-7913
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.

    Cantini, Fabrizio / Goletti, Delia / Petrone, Linda / Najafi Fard, Saied / Niccoli, Laura / Foti, Rosario

    Drugs

    2020  Volume 80, Issue 18, Page(s) 1929–1946

    Abstract: Background: Based on current evidence, recent guidelines of the National Institute of Health, USA indicated the use of remdesivir and dexamethasone for the treatment of COVID-19 patients with mild-moderate disease, not requiring high-flow oxygen. No ... ...

    Abstract Background: Based on current evidence, recent guidelines of the National Institute of Health, USA indicated the use of remdesivir and dexamethasone for the treatment of COVID-19 patients with mild-moderate disease, not requiring high-flow oxygen. No therapeutic agent directed against the immunologic pathogenic mechanisms related to the cytokine release syndrome complicating the disease was indicated.
    Objectives: The purpose of this review was to assess the clinical impact of different therapies for COVID-19; thus, helping to identify the optimal management of the disease. To explain the rationale for the different therapeutic approaches, the characteristics of SARS-CoV-2, the pathogenesis of COVID-19, and the immune response triggered by SARS-CoV-2 infection were reported.
    Methods: The efficacy assessment of the different treatments was performed by a systematic review in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Available English language published articles including randomised controlled trials, open-label trials of antivirals and immune therapies extracted from Medline, Google Scholar, and MedRxiv databases were analysed. For inclusion, the primary end point of the trials had to be the efficacy as measured by the improvement of clinical features, or mortality, or the Intensive Care Unit Admission rate, or the discharge number. Case reports, paediatric studies, and studies without control group were excluded. The literature search was extended up to August 15, 2020.
    Results: After the removal of duplicate articles, and the exclusion of studies not meeting the eligibility criteria, 2 trials of lopinavir/ritonavir, 1 of favipiravir, 3 of remdesivir, 1 of dexamethasone, 3 of hydroxychloroquine, 2 of colchicine, 6 of tocilizumab, 1 of sarilumab, 1 of siltuximab, 2 of anakinra, 3 of baricitinib, 1 of ruxolitinib, 1 of mavrilimumab, and 1 of itolizumab were suitable for the review. Among antivirals, only remdesivir significantly reduced the time to recovery, and mortality. Data for chloroquine and hydroxychloroquine were largely inconclusive. In a large trial, dexamethasone 6 mg/day reduced mortality by one-third. Trials of tocilizumab and sarilumab did not definitively demonstrate efficacy. Anakinra significantly reduced the mortality in 2 trials. Three retrospective trials on a cumulative number of 145 patients, reported the efficacy of baricitinib, with significant reduction of intensive care unit admission, and deaths. These results were recently confirmed by the ACTT-2 trial. Due to paucity of studies and to the small size clinical series, the results of other immune therapies were not conclusive.
    Conclusions: Beyond the supportive therapy, up to now the best therapeutic approach for COVID-19 may be a three-step combination therapy, including remdesivir 100 mg/day (200 mg loading dose on first day) in the first stage of the disease, and combined dexamethasone 6 mg/day plus baricitinib 4 mg/day to target the immune dysregulation triggered by the SARS-CoV-2 infection. The promising results of anakinra should be confirmed by the ongoing RCTs.
    MeSH term(s) Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/therapeutic use ; Alanine/analogs & derivatives ; Alanine/therapeutic use ; Anti-Inflammatory Agents/administration & dosage ; Anti-Inflammatory Agents/therapeutic use ; Antibodies, Monoclonal, Humanized ; Antiviral Agents/administration & dosage ; Antiviral Agents/therapeutic use ; Biological Products/administration & dosage ; Biological Products/therapeutic use ; COVID-19/therapy ; Cytokines/drug effects ; Cytokines/metabolism ; Dexamethasone/therapeutic use ; Drug Therapy, Combination ; Humans ; Inflammation Mediators/metabolism ; Intensive Care Units ; Pandemics ; Retrospective Studies ; SARS-CoV-2 ; COVID-19 Drug Treatment
    Chemical Substances Anti-Inflammatory Agents ; Antibodies, Monoclonal, Humanized ; Antiviral Agents ; Biological Products ; Cytokines ; Inflammation Mediators ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Dexamethasone (7S5I7G3JQL) ; Alanine (OF5P57N2ZX)
    Keywords covid19
    Language English
    Publishing date 2020-10-15
    Publishing country New Zealand
    Document type Journal Article ; Systematic Review
    ZDB-ID 120316-2
    ISSN 1179-1950 ; 0012-6667
    ISSN (online) 1179-1950
    ISSN 0012-6667
    DOI 10.1007/s40265-020-01421-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top